ERIC 2022 | CLL14: feasibility of fixed-duration frontline therapy in CLL
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, shares the long-term results of the Phase III CLL14 study (NCT02242942) comparing venetoclax plus obinutuzumab vs chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia (CLL) in the frontline setting. The study demonstrated the superiority of venetoclax plus obinutuzumab as well as the feasibility of fixed-duration therapy in these patients, and opened relevant clinical questions with regard to certain subgroups and their fitness for such treatment. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
